Coumarin

Coumarin

SCHEMBL21708094

O=[N+]([O-])O.O=c1ccc2ccccc2o1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Coumarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 9/20 0.74
CA9 Q16790 9/20 0.74
MCL1 Q07820 4/20 0.74
CA1 P00915 4/20 0.74
CA3 P07451 4/20 0.74
CA4 P22748 4/20 0.74
CA5A P35218 4/20 0.74
CA7 P43166 4/20 0.74
CA14 Q9ULX7 4/20 0.74
CA5B Q9Y2D0 4/20 0.74
CA2 P00918 3/20 0.74
CA6 P23280 3/20 0.74
TDP1 Q9NUW8 2/20 0.74
LMNA P02545 2/20 0.74
SOST Q9BQB4 1/20 0.74
ALDH1A1 P00352 4/20 0.47
HPGD P15428 4/20 0.47
AKR1B1 P15121 3/20 0.47
KDM4E B2RXH2 2/20 0.47
GLA P06280 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Coumarin SCHEMBL25431834 0.86 CA12 (0.91) CA12CA9MCL1CA1CA3
Coumarin SCHEMBL6252 0.86 CA12 (1.00) CA12CA9MCL1CA1CA3
Coumarin SCHEMBL29385611 0.86 CA12 (1.00) CA12CA9MCL1CA1CA3
Coumarin SCHEMBL3441294 0.86 CA12 (1.00) CA12CA9MCL1CA1CA3
Coumarin SCHEMBL621751 0.86 CA12 (1.00) CA12CA9MCL1CA1CA3
Coumarin SCHEMBL1038138 0.86 CA12 (1.00) CA12CA9MCL1CA1CA3
Coumarin SCHEMBL28886137 0.86 CA12 (1.00) CA12CA9MCL1CA1CA3
Coumarin SCHEMBL11101317 0.84 CA12 (0.87) CA12CA9MCL1CA1CA3
Coumarin SCHEMBL2301559 0.84 CA12 (0.95) CA12CA9MCL1CA1CA3
Coumarin SCHEMBL531571 0.84 CA12 (0.95) CA12CA9MCL1CA1CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210145747-A1 CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF BEIJING INNO MEDICINE CO., LTD. (CN) 2021-05-20 US claimed
US-20200397926-A1 LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING INNO MEDICINE CO., LTD. (CN) 2020-12-24 US claimed
EP-3744317-A1 LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Inno Medicine Co., Ltd. (CN) 2020-12-02 EP claimed
EP-3610859-A1 CERASOME DELIVERY SYSTEM FOR USE IN TARGETED ACTIVATION OF CD44 MOLECULE, PREPARATION METHOD THEREFOR AND USE Beijing Inno Medicine Co., Ltd. (CN) 2020-02-19 EP claimed
US-20240148913-A1 LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING INNO MEDICINE CO., LTD. (CN) 2024-05-09 US disclosed
US-11737977-B2 Cerasome delivery system for targeting activated CD44 molecule, preparation method and use thereof BEIJING INNO MEDICINE CO., LTD. (CN) 2023-08-29 US disclosed
US-20210145747-A1 CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF BEIJING INNO MEDICINE CO., LTD. (CN) 2021-05-20 US disclosed
US-20200397926-A1 LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING INNO MEDICINE CO., LTD. (CN) 2020-12-24 US disclosed
EP-3744317-A1 LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Inno Medicine Co., Ltd. (CN) 2020-12-02 EP disclosed
EP-3610859-A1 CERASOME DELIVERY SYSTEM FOR USE IN TARGETED ACTIVATION OF CD44 MOLECULE, PREPARATION METHOD THEREFOR AND USE Beijing Inno Medicine Co., Ltd. (CN) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210145747-A1 CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF CD44, LDLR, PLAUR CA12 469/4885CA9 1406/4885MCL1 1611/4885
US-11737977-B2 Cerasome delivery system for targeting activated CD44 molecule, preparation method and use thereof CD44, LDLR, PLAUR CA12 469/4885CA9 1406/4885MCL1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.